Equities researchers at Leerink Partners started coverage on shares of Novogen (NASDAQ:KZIA – Get Free Report) in a research note issued on Tuesday, Briefing.com reports. The firm set an “outperform” rating and a $30.00 price target on the stock. Leerink Partners’ price target suggests a potential upside of 282.17% from the company’s current price.
KZIA has been the topic of several other reports. BTIG Research restated a “buy” rating and issued a $40.00 price target on shares of Novogen in a research note on Thursday, September 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Novogen in a research note on Thursday. Finally, Canaccord Genuity Group initiated coverage on shares of Novogen in a research note on Thursday, August 13th. They issued a “buy” rating and a $29.00 price objective for the company. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $29.00.
View Our Latest Stock Report on KZIA
Novogen Price Performance
KZIA opened at $7.85 on Tuesday. Novogen has a fifty-two week low of $4.86 and a fifty-two week high of $17.40. The stock has a fifty day moving average of $11.19 and a 200-day moving average of $11.99.
About Novogen
Novogen Limited was an Australian biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s research centered on small-molecule drug candidates designed to target biological pathways involved in tumor growth and survival.
Novogen’s oncology programs included investigational treatments such as Cantrixil, a therapy intended to target cancer stem cells, and Trilexium, an anticancer compound based on a DNA-damaging mechanism. The company also developed brain-penetrant compounds for the treatment of central nervous system cancers.
In 2016, Novogen changed its name to Kazia Therapeutics Limited and adopted the Nasdaq symbol KZIA.
Recommended Stories
- Five stocks we like better than Novogen
- Amprius Technologies’ Next Big Rally Could Be Taking Shape
- 4 Stocks With Demand So Sticky That the AI Sell-Off Barely Touched Them at All
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
Receive News & Ratings for Novogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen and related companies with MarketBeat.com's FREE daily email newsletter.
